DEFA14A: CytoDyn Advances Oncology Pipeline, Resolves SEC/DOJ Probes

CytoDyn Inc. reports significant progress in its leronlimab oncology program, particularly in mTNBC and mCRC, alongside the closure of SEC and DOJ investigations.

Summary

• CytoDyn is advancing leronlimab as an oncology treatment, focusing on critical unmet needs in solid tumors.
• Robert E. Hoffman has been appointed as the new Chief Financial Officer, bringing extensive industry experience.
• Leronlimab's novel mechanism of action (MOA) in metastatic Triple-Negative Breast Cancer (mTNBC) suggests it induces PD-L1 expression, potentially creating synergy with immune checkpoint inhibitors (ICIs).
• Positive data from mTNBC patients, presented at ESMO, showed promising survival rates (17.9% at 3 and 4 years) and decreased circulating tumor cells (CTCs).
• A follow-up Phase II proof of concept (POC) protocol for PD-L1-negative mTNBC patients will be submitted to the FDA.
• An Expanded Access Protocol (EAP) for second-line, or later, mTNBC patients is being submitted, with funding from an individual benefactor.
• Enrollment is underway for the Phase II study in metastatic Colorectal Cancer (mCRC) with five sites initiated and more onboarding soon.
• A rollover protocol for CRC patients is being prepared to allow continued leronlimab treatment and combination with an ICI for those with disease progression.
• A mTNBC patient unresponsive to Keytruda showed increased PD-L1 levels after leronlimab treatment, supporting the MOA theory.
• SEC and DOJ investigations into the Company have officially closed, with no further action required.
• An oncology advisory board has been established, and a meeting with the FDA has been granted to discuss TNBC data and development plans.
• An individual benefactor is funding an investigator-initiated study in recurrent glioblastoma, anticipated to start in 2026.
• The Alzheimer's study at Cornell University Medical Center has received FDA and IRB approval, with enrollment beginning soon, funded by an outside foundation.
• The LATCH study for HIV+ patients at Oregon Health & Science University has been updated and is ready for IRB/FDA submission, also funded by outside foundations.
• Multiple manuscripts are pending publication, including a comprehensive TNBC manuscript, a mTNBC case report, a safety manuscript, and preclinical studies on CRC and liver conditions.

Sentiment

Score: 9

Explanation: The filing presents highly positive clinical data, particularly in mTNBC, suggesting a novel mechanism of action that could significantly expand treatment options. The resolution of SEC and DOJ investigations removes a major overhang. Multiple new studies are funded and progressing, indicating strong momentum and external validation. The only minor caveat is that these are still early-stage results and forward-looking statements, but the overall tone and content are very optimistic.

Positives

• Appointment of Robert E. Hoffman as CFO, bringing decades of financial and leadership experience to strengthen execution and expand the pipeline.
• Leronlimab's novel mechanism of action in mTNBC, inducing PD-L1 expression, potentially expanding eligibility for immune checkpoint inhibitor (ICI) therapy.
• Promising overall survival rates in mTNBC patients (35.7% at 1 year, 17.9% at 3 and 4 years), comparing favorably with previous studies, especially given the advanced disease state of the study population.
• Median overall survival (mOS) of 6.8 months for all 28 mTNBC patients (9.7 months for those receiving > 525 mg) appears comparable to the current standard of care despite more advanced disease.
• Significant decrease in circulating tumor cells (CTCs) observed in most mTNBC patients after as little as one dose, significantly associated with both progression-free and overall survival.
• 16 out of 21 (76%) mTNBC patients showed a significant increase in PD-L1 expression on CTCs within 30-90 days, with 15 out of 17 (88%) patients on weekly doses of 525 mg or higher showing this shift.
• 100% (5 out of 5) of mTNBC patients who demonstrated significant PD-L1 upregulation and received an ICI are alive 4+ years later, with 60% (3 out of 5) currently having no ongoing evidence of disease.
• Successful closure of both Securities and Exchange Commission (SEC) and Department of Justice (DOJ) investigations with no further requirements for the Company.
• FDA granted a meeting request to discuss TNBC retrospective data and next steps in the development plan, indicating a productive regulatory relationship.
• Funding secured from an individual benefactor for an Expanded Access Protocol (EAP) in mTNBC and an investigator-initiated study in recurrent glioblastoma.
• Funding secured from outside foundations for the Alzheimer's study at Cornell University Medical Center and the LATCH study at Oregon Health & Science University.
• The Alzheimer's study received FDA and IRB approval, with enrollment starting soon.
• The LATCH study has been updated and is ready for IRB/FDA submission.
• Acceptance for publication of the manuscript describing results from the Metabolic Dysfunction-Associated Steatohepatitis study.
• Submission of two additional manuscripts for peer-review, including a preclinical CRC study demonstrating significant reduction in lung metastasis in mice and a study detailing leronlimab's effects on liver fibrosis, inflammation, and fat.

Risks

• Forward-looking statements are based on current expectations, and actual results could vary materially due to inherent risks, uncertainties, and other factors.
• Excessive shareholder outreach to key opinion leaders, potential industry partners, and regulators can inadvertently hinder the Company's progress.

Future Outlook

The Company plans to submit a follow-up Phase II proof of concept protocol for PD-L1-negative mTNBC patients and an Expanded Access Protocol (EAP) for mTNBC. Enrollment in the mCRC Phase II study is ongoing, with plans to submit a rollover protocol to allow continued leronlimab treatment and combination with ICIs for those with disease progression. An investigator-initiated study in recurrent glioblastoma is anticipated to start in 2026. The Alzheimer's study will begin enrollment soon, and the LATCH study is ready for IRB/FDA submission. The Company is actively pursuing collaborations to maximize leronlimab's potential and expects to publish several key manuscripts in the coming weeks and months.

Management Comments

• "We remain confident that addressing critical unmet needs in this field is the best way to build value while improving the lives of patients."
• "The data presented over the past several months marks a watershed moment for both patients and our Company, providing evidence that leronlimab has the potential to reshape treatment paradigms in solid tumor oncology."
• "His expertise in capital markets and strategic planning strengthens our ability to execute, network, and expand our pipeline. We are delighted to have him aboard." (referring to Robert E. Hoffman)
• "I am also pleased to share that we recently received confirmation from both the Securities and Exchange Commission (SEC) and Department of Justice (DOJ) that their respective investigations have now closed, and nothing further is required of the Company."
• "I believe this positive conclusion for the Company is a reflection of our team here and our collective commitment to compliance and cooperation."
• "I remain confident that our collaborative relationship with the FDA has placed us on a productive trajectory."
• "Maintaining strong relationships and credibility with the FDA and industry partners remains a top priority as we move forward."
• "Your support has carried the Company through the last several years and we remain committed to acting in your best interests."
• "Encounters like these remind us why our work matters and fuel our determination to accelerate progress for patients everywhere."

Industry Context

The oncology landscape is rapidly evolving, with immune checkpoint inhibitors (ICIs) becoming a cornerstone of treatment for various solid tumors. However, a significant portion of patients, particularly those with 'cold' tumors or low PD-L1 expression, do not benefit from ICI therapy. CytoDyn's leronlimab, by potentially inducing PD-L1 expression and turning 'cold' tumors 'hot,' could significantly expand the addressable patient population for ICIs in aggressive cancers like mTNBC and mCRC. This novel mechanism of action, if confirmed, represents a potential paradigm shift, offering new therapeutic avenues for patients who currently have limited options and poor prognoses. The focus on mTNBC, an aggressive breast cancer with low 5-year survival rates (around 15%), highlights the critical unmet need CytoDyn aims to address.

Comparison to Industry Standards

• The 5-year survival rates for mTNBC are typically around 15%. CytoDyn's observed 3-year and 4-year survival rates of 17.9% in a study population with advanced disease (failed median of two prior lines, 64% visceral metastases, 29% brain metastases) compare favorably, especially considering other studies often do not report survival rates out to three years.
• The median overall survival (mOS) of 6.8 months for all 28 mTNBC patients (9.7 months for those receiving > 525 mg) appears comparable to the current standard of care, despite the study population generally having more advanced disease than typical clinical populations.
• The finding that 100% (5/5) of mTNBC patients who significantly upregulated PD-L1 and received an ICI are alive 4+ years later, with 60% (3/5) having no ongoing evidence of disease, is a highly significant outcome compared to the typical prognosis for mTNBC patients who have exhausted other options. This contrasts sharply with the finding that none of the 23 patients who didn't induce significant PD-L1 expression or didn't receive an ICI with leronlimab are alive today.
• Up to 85% of patients with mCRC are not currently candidates for ICI therapy due to 'cold' tumors and lack of PD-L1 expression. Leronlimab's potential to induce PD-L1 expression could make a substantial portion of these patients eligible for ICI treatment, a significant improvement over current standards.

Management Changes

Corporate Governance

Legal Proceedings

• The Securities and Exchange Commission (SEC) investigation has closed, with nothing further required of the Company.
• The Department of Justice (DOJ) investigation has closed, with nothing further required of the Company.

Stakeholder Impact

• Shareholders: Positive impact due to significant clinical progress, potential for value creation from leronlimab, and resolution of major regulatory investigations (SEC/DOJ). Shareholders are asked to be mindful of outreach to third parties to avoid hindering progress.
• Patients: Potential for new and improved treatment options, especially for aggressive cancers like mTNBC and mCRC where current options are limited. Expanded Access Protocol (EAP) offers compassionate use.
• Employees: Positive impact from company progress, new CFO appointment, and resolution of regulatory issues, potentially leading to increased stability and growth opportunities.
• Regulators (FDA): Company is maintaining strong relationships and credibility, with granted meeting requests, indicating a productive trajectory.
• Industry Partners: Novel MOA and clinical data are attracting attention, leading to active pursuit of collaborations.

Next Steps

• Submit a follow-up Phase II proof of concept (POC) protocol for PD-L1-negative mTNBC patients to the FDA.
• Submit an Expanded Access Protocol (EAP) for second-line, or later, mTNBC patients.
• Continue enrollment in the Phase II mCRC study, with the fifth patient's enrollment triggering a Data Safety Monitoring Board (DSMB) safety review.
• Submit a rollover protocol for CRC patients to allow continued leronlimab treatment and combination with ICIs for those with disease progression.
• Closely track PD-L1 levels of enrolled CRC patients to validate the MOA.
• Initiate an investigator-initiated study in recurrent glioblastoma (anticipated start in 2026).
• Begin enrollment in the Alzheimer's study at Cornell University Medical Center.
• Submit the updated LATCH study for IRB and FDA approval.
• Prepare and submit a comprehensive TNBC manuscript for internal review and peer review.
• Submit a mTNBC case report manuscript for peer review.
• Prepare and submit a safety manuscript summarizing leronlimab safety data.
• Engage in critical conversations with key opinion leaders, potential industry partners, and regulators.
• Actively pursue collaborations to maximize leronlimab's potential.

Key Dates

Recommendation

The filing presents compelling evidence of leronlimab's potential as a transformative oncology treatment, particularly in mTNBC, where it demonstrated promising survival rates and a novel mechanism of action (PD-L1 upregulation) that could significantly expand the utility of immune checkpoint inhibitors. The 100% survival rate in a subset of mTNBC patients who received leronlimab and an ICI, with 60% achieving no evidence of disease after 4+ years, is a remarkable outcome for a patient population with very poor prognosis. Furthermore, the successful closure of both SEC and DOJ investigations removes a major regulatory overhang that has likely suppressed the stock. With multiple clinical programs advancing, new funding secured for studies, and a strengthened management team, the company appears to be on a strong positive trajectory. These factors collectively suggest a significant undervaluation given the de-risking events and clinical potential, warranting a "strong buy" recommendation for seasoned investors.

Keywords

CytoDyn, leronlimab, oncology, mTNBC, Metastatic Triple-Negative Breast Cancer, mCRC, Metastatic Colorectal Cancer, Glioblastoma, HIV, Alzheimer's, PD-L1, Immune Checkpoint Inhibitors, ICI, CCR5, clinical trials, FDA, SEC investigation, DOJ investigation, biotechnology, drug development, cancer treatment, circulating tumor cells, CTC